Completed PHASE3 NCT00105547

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type

Sponsor: Myrexis Inc.

Conditions Alzheimer Disease Dementia

Interventions MPC-7869

Updated 7 times since 2017 Last updated: May 3, 2009 Started: Feb 28, 2005 Completion: May 31, 2008

A PHASE3 clinical study on Alzheimer Disease and Dementia, this trial is completed. The trial is conducted by Myrexis Inc. and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Myrexis Inc.

Data source: Myrexis Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alabaster, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Atlanta, United States , Austin, United States , Bala-Cynwyd, United States , Baltimore, United States , Bay Harbor, United States , Beaufort, United States and 103 more locations